Antiplatelet drug vs control
Antiplatelet drug probably leads to lower death or dependence at end of compared with control (moderate certainty).
- Peto OR 0.95 [0.91, 0.99]7 studies · 42034 participantsModerate
Antiplatelet drug probably leads to lower death or dependence at end of compared with control (moderate certainty).
It is very uncertain whether antiplatelet drug changes death from any cause during compared with control (very low certainty).
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
Antiplatelet drug probably leads to higher complete recovery from stroke (post hoc) compared with control (moderate certainty).
Summary of findings table ‐ Platelet transfusion probably leads to higher death or dependence (mRS 4–6) compared with open control (moderate certainty).
Summary of findings table ‐ Platelet transfusion showed no clear difference in intracerebral haemorrhage expansion by 24 hours compared with open control (moderate certainty).
Summary of findings table ‐ Platelet transfusion showed no clear difference in all serious adverse events compared with open control (moderate certainty).
Summary of findings table ‐ Platelet transfusion showed no clear difference in death from any cause compared with open control (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.